European Patent Office

T 0990/96 (Erythro-compounds/NOVARTIS) du 12.02.1998

Identifiant européen de la jurisprudence
ECLI:EP:BA:1998:T099096.19980212
Date de la décision
12 février 1998
Numéro de l'affaire
T 0990/96
Requête en révision de
-
Numéro de la demande
93106005.7
Classe de la CIB
C07C 69/732
Langue de la procédure
Anglais
Distribution
Publiées au Journal officiel de l'OEB (A)
Téléchargement
Décision en anglais
Autres décisions pour cet affaire
-
Résumés pour cette décision
-
Titre de la demande
Acides hept-6-énoiques et heptanoiques substitués sur la position 7 et dérivés de ceux-ci
Nom du demandeur
Novartis AG
Nom de l'opposant
Novartis AG
Chambre
3.3.01
Sommaire

1. It is common practice for a person skilled in the art of preparative organic chemistry to (further) purify a compound obtained in a particular chemical manufacturing process according to the prevailing needs and requirements. Since, as a rule, conventional methods for the purification of low molecular organic compounds are within his common general knowledge, a document disclosing a low molecular chemical compound and its manufacture makes normally available this compound to the public in the sense of Article 54 EPC in all desired grades of purity (no. 7 of the reasons for the decision).

2. If a party alleges that this general rule would not be applicable in a particular case, then the burden of proving the existence of such an exceptional situation, e.g. of a situation where all prior attempts to achieve a particular degree of purity by conventional purification processes have failed, lies with the party who alleges such a situation (no. 8 of the reasons for the decision).

Dispositions juridiques pertinentes
European Patent Convention Art 54 1973
Mots-clés
Novelty (no)
Purity of chemical compound no new element
Exergue
-

ORDER

For these reasons it is decided that:

The appeal is dismissed.